DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 14:04:18 2024-06-20 EDT | ||
| 35.15 EUR | +0.17% |
|
| Current month | +1.33% | ||
| 1 month | -0.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 35.15 | +0.17% |
| 24-06-19 | 35.09 | +0.23% |
| 24-06-18 | 35.01 | -0.26% |
| 24-06-17 | 35.1 | -0.82% |
| 24-06-14 | 35.39 | +0.25% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 02:04 pm
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM5UQ9 |
| ISIN | DE000VM5UQ98 |
| Date issued | 2023-11-22 |
| Maturity | 2024-09-20 (92 Days) |
| Parity | 1 : 1 |
| Emission price | 34.59 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 36.33 € |
|---|---|
| Lowest since issue | 33.72 € |
| Spread | 0.06 € |
| Spread % | 0.17% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.81
USD
Average target price
53.19
USD
Spread / Average Target
+30.35%
- Stock Market
- Certificates
- Certificat
